Tag Archives: GlaxoSmithKline

Judgment Day for Avandia

By Oriana Schwindt | Published: July 14, 2010
Judgment Day has finally arrived for GSK’s Avandia. FDA’s Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management Advisory Committees met July 13 and 14 to finally recommend, after months of deck-stacking against GSK, that the drug be severely restricted, if not outright pulled from the market. In the vote, 12 of 33 panelists [...]
Posted in FDA, Regulatory | Also tagged , , , , , , | Leave a comment

Avandia on Trial

By Walter Armstrong | Published: July 12, 2010
The mid-July FDA advisory committee meeting to decide the fate of GlaxoSmithKline’s Avandia (rosiglitazone) is widely viewed as a test case of how the agency’s new leadership will address controversial drugs with serious risks but confusing data. A request that GSK yank its diabetes blockbuster—three years after first being associated with an increased risk of [...]
Posted in Legal | Also tagged , , , , , , | Leave a comment

GSK Scores High in Market Access

By George Koroneos | Published: June 23, 2010
GlaxoSmithKline ranked number one in a study of pharmaceutical companies offering access to medicines to emerging and developing nations, proving that the UK drug giant has a far stronger grasp on new markets than its US and Japanese counterparts. The study ranks 20 companies based on significant criteria including pricing, patents and intellectual properties, capacity enhancement, [...]
Posted in Emerging Markets, Strategy | Also tagged , , , , , , | Leave a comment

AstraZeneca to Slash 8,000 More Jobs (Updated 2/3/10)

By Oriana Schwindt | Published: January 28, 2010
Last year, AstraZeneca announced the elimination of some 15,000 jobs. Last Thursday, the London-based company revealed that it plans to lay off another 8,000 by 2014—this despite global revenue growth of 4 percent for 2009. Much of the drive for this addition labor sculpting stems from AZ’s desire to streamline its R&D; the company will focus [...]
Posted in Strategy | Also tagged , , , , , , , | 1 Comment

One to Watch: Q&A with Paul Dyer

By Brittany Agro | Published: December 10, 2009
Paul Dyer, eMedia Director, WeissComm Group (WCG), is already on his way to the top not only on PR News’ 15 to watch list, but also as an emerging leader in the online healthcare landscape. At 26, Paul Dyer has a long list of accolades that most young professionals his age only dream about. As eMedia [...]
Posted in Marketing, People | Also tagged , , , , , , | Leave a comment